Literature DB >> 7093106

Intravenous labetalol in severe hypertension.

C Dal Palu, A C Pessina, A Semplicini, M Hlede, F Morandin, P Palatini, G Sperti, G P Rossi.   

Abstract

1 Labetalol was administered by intravenous infusion or by the combination of intravenous bolus injection plus infusion to 15 patients with severe essential hypertension and to one with phaeochromocytoma. 2 With the infusion alone the reduction of arterial pressure was slow to develop and limited in degree, but with the combination of the bolus injection plus the infusion the reduction in pressure was more prompt, more pronounced and longer lasting. Apart from an uncomplicated syncopal attack in one patient, no serious side--effects were encountered. 3 Subsequent treatment with oral labetalol usually required the addition of a diuretic to control the blood pressure probably due to sodium and fluid retention during treatment with labetalol alone.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093106      PMCID: PMC1401825          DOI: 10.1111/j.1365-2125.1982.tb01896.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.

Authors:  P Weidmann; R De Chătel; W H Ziegler; J Flammer; F Reubi
Journal:  Am J Cardiol       Date:  1978-03       Impact factor: 2.778

2.  Treatment of severe hypertension by repeated bolus injections of labetalol.

Authors:  A M Cumming; J J Brown; A F Lever; A Mackay; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Routine measurement of glycosylated haemoglobin.

Authors:  R G Ryall; J J Graham
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

4.  Labetalol in hypertension.

Authors: 
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

5.  Emergency treatment of severe hypertension with intravenous labetalol.

Authors:  B P McGrath; P G Matthews; N M Walter; B W Maydom; C I Johnston
Journal:  Med J Aust       Date:  1978-10-21       Impact factor: 7.738

6.  Labetalol in hypertensive emergencies.

Authors:  E P MacCarthy; G W Frost; G S Stokes
Journal:  Med J Aust       Date:  1978-04-08       Impact factor: 7.738

7.  Autoregulation of brain circulation in severe arterial hypertension.

Authors:  S Strandgaard; J Olesen; E Skinhoj; N A Lassen
Journal:  Br Med J       Date:  1973-03-03
  7 in total
  7 in total

Review 1.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

2.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Current management of hypertensive emergencies.

Authors:  J Y Garcia; D G Vidt
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 5.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 6.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 7.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.